FORM 4

Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box if no longer subject to

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 20349

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Schuth Alexander O.					2. Issuer Name and Ticker or Trading Symbol  Denali Therapeutics Inc. [ DNLI ]								eck all application	,		10% Ow Other (s below)	ner
(Last) (First) (Middle) C/O DENALI THERAPEUTICS INC.					3. Date of Earliest Transaction (Month/Day/Year) 02/26/2018								COO and Secretary				
151 OYSTER POINT BOULEVARD, SECOND FLOOR																	
(Street)				—   <sup>4.</sup>	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line)				
SOUTH SAN FRANCISCO CA			94080											led by Mor		rting Person One Report	
(City)	(S	tate)	(Zip)														
		Та	ble I - Non-De	erivati	ve S	ecurities	s Ac	quired, I	Disp	osed c	of, or Be	neficially	/ Owned				
Date						2A. Deemed Execution Date, if any (Month/Day/Year		Code (Instr.					Beneficia Owned F	s ally ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	: Direct I Indirect E str. 4)	7. Nature of Indirect Beneficial Ownership
					Code			v	Amount	(A) (D)	Price	Reported Transacti (Instr. 3 a	on(s)			Instr. 4)	
			Table II - Der (e.g					uired, Di s, option					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	ion(s)		
Stock Option (right to buy)	\$22.16	02/26/2018		A		180,000		(1)	0:	2/25/2028	Common Stock	180,000	\$0.00	180,0	00	D	

## **Explanation of Responses:**

1.25% of the shares subject to the option will vest on February 26, 2019 and an additional 1/48 of the shares vest monthly thereafter.

## Remarks:

<u>/s/ Tyler Nielsen, by power of attorney</u>

\*\* Signature of Reporting Person Date

02/28/2018

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.